Public Employees Retirement System of Ohio Purchases Shares of 26,103 Keros Therapeutics, Inc. $KROS

Public Employees Retirement System of Ohio purchased a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 26,103 shares of the company’s stock, valued at approximately $348,000. Public Employees Retirement System of Ohio owned 0.06% of Keros Therapeutics at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of KROS. FNY Investment Advisers LLC acquired a new position in Keros Therapeutics in the first quarter valued at approximately $25,000. CWM LLC lifted its holdings in Keros Therapeutics by 10,157.7% in the first quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after acquiring an additional 2,641 shares during the period. Entropy Technologies LP acquired a new position in Keros Therapeutics in the first quarter valued at approximately $121,000. AlphaQuest LLC lifted its holdings in Keros Therapeutics by 268.0% in the first quarter. AlphaQuest LLC now owns 13,234 shares of the company’s stock valued at $135,000 after acquiring an additional 9,638 shares during the period. Finally, Corebridge Financial Inc. lifted its holdings in Keros Therapeutics by 6.4% in the first quarter. Corebridge Financial Inc. now owns 16,212 shares of the company’s stock valued at $165,000 after acquiring an additional 972 shares during the period. 71.56% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on KROS. Bank of America downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the company from $32.00 to $18.00 in a report on Tuesday, June 10th. HC Wainwright decreased their price target on Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a report on Friday, August 8th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Keros Therapeutics in a research report on Saturday, September 27th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $30.00.

Keros Therapeutics Stock Performance

Shares of KROS opened at $15.62 on Tuesday. The stock has a 50 day moving average price of $15.11 and a 200 day moving average price of $14.00. The stock has a market capitalization of $634.48 million, a price-to-earnings ratio of 50.39, a PEG ratio of 2.05 and a beta of 0.97. Keros Therapeutics, Inc. has a one year low of $9.12 and a one year high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.38. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $3.83 million. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The firm’s revenue for the quarter was up 49002.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.25) earnings per share. On average, analysts predict that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.